NZCR works with global pharmaceutical and biotechnology companies to investigate potential new medicines and has competed over 35 biosimilar studies.

This randomised, phase 1 study comparing the pharmacokinetics of a bevacizumab biosimilar to EU and USA sourced bevacizumab, involved 119 healthy males participants and was completed at ACS and CCST in 2018.

NZCR CEO and COO, Drs Christian Schwabe and Dr Chris Wynne are authors of this recent Bevacizumab biosimilar publication.


Get in touch today

NZCR Advancing global health